Atlas company financials

IONIS PHARMACEUTICALS INC

Standardized 18-year financial series for IONIS PHARMACEUTICALS INC, built from filing-derived source data and exposed in JSON, CSV, and XLSX so it can feed iterFact artifacts or analyst workflows without hand-entering the numbers.

United StatesCIK 0000874015FY2008 → FY2025

Open JSON Download CSV Download XLSX Quarterly JSON Summary JSON Filing index

Latest fiscal year

FY2025

Revenue

$943.7M

Adjusted EBITDA

—

Net result

-$381.4M

Net financial debt

$1.4B

Latest source: FY2025 filing · published data snapshot generated April 26, 2026

Phase 2 summary

Latest quarter, TTM, and growth are now pre-computed for chat and templates.

Latest quarter revenue

$156.7M

TTM revenue

$874.2M

TTM free cash flow

—

Latest quarter net result

-$128.6M

Quarterly coverage: 50 periods · latest quarter FY2025-Q3 · TTM revenue growth 29.1%.

What this gives you

A proof-of-concept company data surface, not a dead PDF shelf.

The same standardized payload behind this page is exposed through downloadable CSV and XLSX files plus a stable JSON route. That makes it usable as a live input to iterFact templates, a spreadsheet handoff, or a future API surface without re-normalizing the source documents again.

Source audit

Official links first, raw iterFact payloads right next to them.

Official sources

SEC EDGAR companyfacts
comparative · ionis-pharmaceuticals-inc-fy2008 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2011-03-01 · Retrieved: 2026-04-26T11:46:52.148155+00:00
SEC EDGAR companyfacts
primary · ionis-pharmaceuticals-inc-fy2011 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2012-02-29 · Retrieved: 2026-04-26T11:46:52.148155+00:00
SEC EDGAR companyfacts
primary · ionis-pharmaceuticals-inc-fy2012 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2013-02-28 · Retrieved: 2026-04-26T11:46:52.148155+00:00
SEC EDGAR companyfacts
primary · ionis-pharmaceuticals-inc-fy2013 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2014-03-03 · Retrieved: 2026-04-26T11:46:52.148155+00:00
SEC EDGAR companyfacts
us-gaap:NetIncomeLoss · us gaap companyfacts · comparative · ionis-pharmaceuticals-inc-fy2013 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2016-02-26 · Retrieved: 2026-04-26T11:46:52.148155+00:00

Ten-year series

Headline company financials by fiscal year

Fiscal year	Revenue	Adj. EBITDA	EBIT	Net result	Op. cash flow	Capex	Net debt	Status
FY2008	107M	—	-13M	-18M	212M	-14M	—	comparative annual fact carried from later 10k · missing accounts receivable · missing adjusted ebitda · missing cost of revenue · missing current assets · missing current liabilities · missing gross profit · missing inventory · missing net financial debt · missing sg and a · missing total assets
FY2009	122M	—	-28M	155M	-108M	-13M	—	comparative annual fact carried from later 10k · missing accounts receivable · missing adjusted ebitda · missing cost of revenue · missing gross profit · missing inventory · missing net financial debt · missing sg and a
FY2010	108M	—	-48M	-61M	-64M	-13M	—	missing accounts receivable · missing adjusted ebitda · missing cost of revenue · missing gross profit · missing inventory · missing net financial debt · missing sg and a
FY2011	99M	—	-71M	—	-115M	-7M	—	missing accounts receivable · missing adjusted ebitda · missing cost of revenue · missing gross profit · missing inventory · missing net financial debt · missing net result · missing sg and a
FY2012	102M	—	-69M	—	2M	-1M	—	missing accounts receivable · missing adjusted ebitda · missing basic eps · missing cost of revenue · missing diluted eps · missing gross profit · missing inventory · missing net financial debt · missing net result · missing sg and a
FY2013	147M	—	-52M	-61M	63M	-2M	—	missing accounts receivable · missing adjusted ebitda · missing basic eps · missing cost of revenue · missing diluted eps · missing gross profit · missing inventory · missing net financial debt · missing sg and a

Filing provenance